China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
May 29 2008 - 9:00AM
PR Newswire (US)
TAIAN CITY, China, May 29 /Xinhua-PRNewswire-FirstCall/ -- China
Biologic Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO) ("CBP,"
or the "Company"), one of the leading plasma-based pharmaceutical
companies in the People's Republic of China ("China" or the "PRC"),
today announced that the Company has been approved by the Chinese
State Food and Drug Administration (the "SFDA") to commence the
production of Human Albumin 12.5g/vial (25%, 50 ml). Human Albumin
12.5g/vial (25%, 50 ml), contains the highest concentration and
delivers the highest dosage of the Human Albumin family products in
Mainland China, and has a better effect on the clinical application
for ascites due to liver cirrhosis, external injuries,
hydrocephalus due to cerebral hemorrhage, serious hypoproteinemia,
and other major diseases. With this approval, CBP is now one of the
few producers offering the widest range of Human Albumin products
available in China. "We are pleased to receive approval from the
SFDA to produce this concentration and dosage of Human Albumin,"
said Mr. Chaoming Zhao, CFO of China Biologic. "The approval
represents a significant milestone for our Company." The Company
has already commenced the production and marketing of this new
product. About China Biologic Products, Inc. Through its indirect
majority-owned subsidiary Shandong Taibang Biological Products Co.
Ltd., China Biologic Products, Inc. (the "Company"), is principally
engaged in the research, development, production and manufacturing
and sale of plasma-based biopharmaceutical products to hospitals
and other health care facilities in China. The Company's human
albumin products are mainly used to increase blood volume and its
immunoglobulin products are used for the treatment and prevention
diseases. Safe Harbor Statement This release may contain certain
"forward-looking statements" relating to the business of China
Biologic Products, Inc. and its subsidiary companies. All
statements, other than statements of historical fact included
herein are "forward-looking statements," including statements
regarding: the significance of the new Human Albumin product to the
Company, the ability of the Company to achieve its commercial
objectives; the business strategy, plans and objectives of the
Company and its subsidiaries; and any other statements of non-
historical information. These forward-looking statements are often
identified by the use of forward-looking terminology such as
"believes," "expects" or similar expressions, involve known and
unknown risks and uncertainties. Although the Company believes that
the expectations reflected in these forward-looking statements are
reasonable, they do involve assumptions, risks and uncertainties,
and these expectations may prove to be incorrect. Investors should
not place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. The Company's
actual results could differ materially from those anticipated in
these forward-looking statements as a result of a variety of
factors, including those discussed in the Company's periodic
reports that are filed with the Securities and Exchange Commission
and available on its website (http://www.sec.gov/). All forward-
looking statements attributable to the Company or persons acting on
its behalf are expressly qualified in their entirety by these
factors. Other than as required under the securities laws, the
Company does not assume a duty to update these forward-looking
statements. For more information, please contact: Company Contact:
Mr. Y. Tristan Kuo Vice President, Finance China Biologic Products,
Inc. Tel: +86-538-6202206 Email: Web: http://www.chinabiologic.com/
Investor Relations Contact: Mr. Crocker Coulson President CCG Elite
Investor Relations Tel: +1-646-213-1915 (NY office) Email: Web:
http://www.ccgelite.com/ DATASOURCE: China Biologic Products, Inc.
CONTACT: Company Contact: Mr. Y. Tristan Kuo, Vice President,
Finance of China Biologic Products, Inc., +86-538-6202206, or ;
Investor Relations Contact: Mr. Crocker Coulson, President of CCG
Elite Investor Relations, +1-646-213-1915 (NY office), or
Copyright